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This study explored the effects of cucurbitacin E (CuE), a bioactive compound from Cucurbitaceae, on the metabolism/  
pharmacokinetic of tolbutamide, a model CYP2C9/11 probe substrate, and hepatic CYP2C11 expression in rats. Liquid chro-
matography-(tandem) mass spectrometry (LC-MS/MS) assay was used to detect tolbutamide as well as 4-hydroxytolbutamide, 
and then successfully applied to the pharmacokinetic study of tolbutamide in rats. The effect of CuE on CYP2C11 expression 
was determined by western blot. CuE (1.25–100 μmol L1) competitively inhibited tolbutamide 4-hydroxylation (CYP2C11) 
activity only in concentration-dependent manner with a Ki value of 55.5 μmol L1 in vitro. In whole animal studies, no signifi-
cant difference in metabolism/pharmacokinetic of tolbutamide was found for the single pretreatment groups. In contrast, mul-
tiple pretreatments of CuE (200 µg kg1 d1, 3 d, i.p.) significantly decreased tolbutamide clearance (CL) by 25% and pro-
longed plasma half-time (T1/2) by 37%. Moreover, CuE treatment (50–200 µg kg
1 d1, i.p.) for 3 d did not affect CYP2C11 
expression. These findings demonstrated that CuE competitively inhibited the metabolism of CYP2C11 substrates but had no 
effect on rat CYP2C11 expression. This study may provide a useful reference for the reasonable and safe use of herbal or nat-
ural products containing CuE to avoid unnecessary drug-drug interactions. 
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Cytochrome P450 (CYP) enzymes belong to a super family 
of haem-proteins that play an important role in catalyzing 
the oxidation of many endogenous and exogenous sub-
stances. CYP enzymes are primarily located in the liver, as 
well as widely distributed in other tissues, such as intestine, 
lung, kidney, and brain [1]. Drug-drug interactions (DDI) 
usually occur as CYP have broad substrate specificity and 
overlapping substrate selectivity [2]. Up to now, DDI have 
become more common as a result of polypharmacy and the 
increasing use of alternative medicine, including herbs and 
natural products [3]. In particular, CYP inhibition after ex-
posure to different drugs and chemicals is directly linked to 
a number of drug-induced toxicity [2]. Therefore, much 
attention should be paid to assess the CYP inhibitory prop-
erties of drugs and chemicals especially in the early stage of 
the discovery.  
The Cucurbitaceae family, mainly in tropical and   
subtropical regions, ranks among the highest of plant fami-
lies for number and percentage of species used as human 
food [4]. Advances in separation techniques have enabled 
the isolation and chemical characterization of the active 
components of Cucurbitaceae, with extensive research cur-
rently undertaken to investigate the pharmacology of the 
individual components of the plant [4,5]. Cucurbitacin E 
(CuE, Figure 1), one of the major triterpenoid of Cucurbi-  
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Figure 1  Chemical structure of cucurbitacin E.  
taceae, has been reported to possess a number of pharma-
cological properties such as anti-inflammatory [6,7], an-
ti-tumor [8–12], and immunomodulatory activities [13]. 
Previous studies in our laboratory have also shown that CuE 
inhibits tumor angiogenesis through VEGFR2-mediated 
Jak2-STAT3 signaling pathway [9], and inhibits breast tumor 
metastasis by suppressing cell migration and invasion [11]. In 
addition, some herbal products containing CuE such as cu-
curbitacin tablets/capsules have been widely used in China 
to treat liver diseases [14]. However, the interactions be-
tween CuE and CYP enzymes remain unclear. 
Recently, we reported CuE-warfarin interactions invol- 
ved possible underlying pharmacodynamic and pharmaco-
kinetic mechanisms [15]. CuE not only exaggerated the 
pharmacological effects of warfarin by prolonging the pro-
thrombin time, an indicator of anticoagulation action, but 
also decreased the elimination of warfarin in rats [15]. 
Warfarin is metabolized through different CYP metabolic 
pathways, such as via CYP1A2 to form 6-hydroxy- and 
8-hydroxy-warfarin, CYP2C9 to form 6-hydroxy- and 
7-hydroxy-warfarin, and CYP3A4 to 4-hydroxy- and 
10-hydroxy-warfarin [16–18]. Hence warfarin is not an ide-
al model substrate to investigate the potential inhibition of 
CuE for the individual CYP isoforms. In this study, the ef-
fects of CuE on CYP2C11 activity were investigated in 
vitro and in vivo in the rat, using the probe substrate tol-
butamide and LC-MS/MS method. Moreover, the western 
blot analysis was also used to determine the effect of CuE 
on hepatic CYP2C11 expression.  
1  Materials and methods 
1.1  Chemicals and reagents 
Tolbutamide, chlorpropamide, sulfaphenazole, glucose 6- 
phosphate (G6P), glucose 6-phosphate dehydrogenase 
(G6PDH), -nicotinamide adenine dinucleotide phosphate 
(NADP), and tris (hydroxymethyl) aminomethane hydro-
chloride (Tris-HCl) were purchased from Sigma Chemical 
Co. (USA). 4-hydroxytolbutamide was obtained from To-
ronto Research Chemical (CA). Cucurbitacin E (puri-
ty>98%) was purchased from Shanghai Zhanshu Chemical 
Technology Co. (Shanghai). Fluconazole was supplied by 
Energy Chemical (Shanghai). Carbamazepine was obtained 
from J&K Scientific Co. (Beijing). Acetonitrile (ACN) and 
methanol (all high performance liquid chromatography 
(HPLC) grade) were purchased from Merck (Germany). 
Acetic acid glacial (HPLC grade) was purchased from 
TEDIA (USA). Ethyl acetate (HPLC grade) was purchased 
from Fisher chemicals (UK). Distilled water was purified in 
a Millipore system Milli Q. 
1.2  Animals 
Male Sprague-Dawley (SD) rats (200–250 g) were pur-
chased from National Rodent Laboratory Animal Re-
sources, Shanghai Branch of China. The animals were kept 
in animal holding room under standard conditions with 12 h 
light-dark cycles, with free access to rodent cubes and tap 
water. Animals were maintained according to the National 
Institutes of Health standards established in the “Guidelines 
for the Care and Use of Experimental Animals”, and all the 
experimental protocols were approved by the Ethical Com-
mittee on Animal Experimentation of the East China Nor-
mal University (Shanghai). 
1.3  Preparation of rat liver microsomes 
In this study, the rats (200–250 g) were fasted overnight and 
killed by cervical dislocation before removal of the liver. 
The liver was excised, rinsed with ice-cold saline (0.9% 
NaCl w/v), weighed and homogenised in a 0.05 mmol L1 
Tris/KCl buffer (pH 7.4). The homogenate was centrifuged 
at 10,000×g at 4°C for 30 min. The supernatant was then 
centrifuged at 105,000×g at 4°C for 60 min. The pellet was 
reconstituted with 0.05 mmol L1 Tris/KCl buffer (pH 7.4) 
and stored at 150°C until used. The protein concentration 
was determined by a protein quantitative assay using bicin-
choninic acid [19]. Cytochrome P450 content of the rat liver 
microsomes was quantified as previously described [20]. 
1.4  Analysis of rat CYP2C11 enzyme activity 
The effects of CuE on CYP2C11 activity in rat liver    
microsomes in vitro were evaluated by adding CuE at  
various concentrations (1.25–100 µmol L1) to tolbutamide 
(50 µmol L1). Control incubations for tolbutamide 4-  
hydroxylation did not contain CuE. Liver microsomes    
(1 mg mL1) were incubated with 0.05 mol L1 Tris/HCl 
buffer (pH 7.4) with NADPH regenerating system (1 mmol L1 
NADP, 5 mmol L1 G6P, 1 unit mL1 G6PDH, and       
5 mmol L1 magnesium chloride). The incubation mixtures 
were incubated in an Eppendorf Thermomixer at 800 rev 
min1 at 37°C. The reaction was initiated by adding the 
NADP into incubation mixture. Termination of the enzyme 
reaction was by addition of 500 µL of ice-cold acetonitrile. 
The HPLC analysis of 4-hydroxytolbutamide was as previ-
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ously described [21]. The inhibitory effect of CuE on 
CYP2C11 was evaluated by the percentage of the formation 
of 4-hydroxytolbutamide compared with the control.  
1.5  Analysis of inhibition kinetics  
To determine the mechanism of CuE inhibition of tolbut-
amide 4-hydroxylase, a range of tolbutamide (25, 50, 75, 
100 µmol L1) and CuE (5, 10, 25, 50 µmol L1) concentra-
tions were used for inhibition kinetics studies. Sulfaphena-
zole (5–50 µmol L1), a selective rat CYP2C11 inhibitor, 
was used as a positive control [21,22]. The mode of inhibi-
tion was evaluated by visual inspection of Lineweaver-Burk 
plots, which were obtained from Michaelis-Menten 
non-linear regression equation. The inhibition constant (Ki) 
was obtained by a secondary plot using the slope of the 
primary Lineweaver-Burk plot (Km/Vmax versus inhibitor 
concentration) and fitted by GraphPad Prism 5.0 (GraphPad 
Software Inc., USA). 
1.6  Analysis of time-dependent inhibition 
To investigate whether inhibition of CYP2C11 by CuE was 
time-dependent, time-dependent inhibition experiments 
were carried out [23]. Primary incubations included CuE 
(final concentration approaching IC50), 0.05 mol L
1 
Tris/HCl buffer (pH 7.4), 5 mmol L1 MgCl2, 1 mmol L1 
NADP, 5 mmol L1 G6P, 1 unit mL1 G6PDH and        
1 mg mL1 microsomal protein. The mixture was incubated 
at 37°C for various time points (0, 5, 10, and 20 min). At 
each pre- incubation time point, 50 µL aliquots of the pri-
mary incubation mixtures were transferred to a secondary 
incubation to a final volume of 500 µL, which included   
50 μmol L1 tolbutamide,1 mmol L1 NADP, 5 mmol L1 
G6P, 1 unit mL1 G6PDH, and 5 mmol L1 magnesium 
chloride, and 0.05 mol L1 Tris/HCl (pH 7.4). The tolbut-
amide mixture was incubated at 37°C for 90 min and 
stopped by the addition of 500 µL of ice-cold acetonitrile. 
The samples were treated as described above and then sub-
ject to HPLC analysis. 
1.7  Effects of CuE treatments on the pharmacokinetics 
of tolbutamide 
Intraperitoneal administration of CuE was selected in this 
study over the oral route of administration because our pre-
vious report suggested possible interaction between CYP3A 
and CuE [24]. Significant gastrointestinal absorption and 
first pass metabolism by CYP3A in the small intestine and 
CYP3A-linked drug transporter proteins such as P-gp may 
thus influence the interpretation of the CYP2C11 data in 
this study. For the acute treatments, rats were treated with 
CuE (50–200 µg kg1, i.p.), or saline with 0.1% dimethyl 
sulfoxide (DMSO) (control). A single dose of tolbutamide 
(10 mg kg1) was given via caudal vein 60 min after the 
treatment with CuE. The dosage of tolbutamide used was 
based on similar herb-drug interaction study carried out 
previously [21]. Serial blood samples (approximately 0.5 mL) 
were collected via the orbital venous plexus at 10, 20, 30, 
60, 90, 120, 240 and 360 min after tolbutamide administra-
tion. Plasma was separated and stored at 20°C prior to 
analysis by LC-MS/MS. Fluconazole (60 mg kg1, i.p.) was 
used as a positive control for enzyme inhibition studies [25]. 
For the 3 d treatments, rats were pre-treated with CuE 
(50–200 µg kg1 day1, i.p.) or saline with 0.1% DMSO 
(control, i.p.) for 3 d. During the pre-treatment period, the 
rats were kept in a 12 h light/dark cycle animal room with 
controlled temperature and humidity. Free access to labora-
tory rodent diet and tap water was allowed. One day after 
the final pre-treatment, the rats were injected tolbutamide 
(10 mg kg1) via caudal vein and experiments were per-
formed as described in previous section. Carbamazepine  
(60 mg kg1 day1, i.p., 3 d) was used as a positive control 
for enzyme induction [26]. 
1.8  Plasma sample preparation 
Liquid-liquid extraction in an acidic environment was used 
to extract tolbutamide, 4-hydroxytolbutamide and chlor-
propamide (IS) from the rat plasma. IS solution (5 µL, 1 µg 
mL1 in methanol) and deionized water containing 1% ace-
tic acid (5 µL) were added into the rat plasma (50 µL), and 
then extracted by ethyl acetate (400 µL) via acute vortex. 
The well-vortexed solution was then centrifuged at 
16,000×g for 10 min to separate the organic layer and pre-
cipitation. The organic layer (300 µL) was then quantita-
tively transferred to a new EP tube and evaporated to dry-
ness at 37°C under a gentle stream of nitrogen gas. The res-
idue was re-dissolved in 500 µL of initial mobile phase 
(H2O:ACN=65:35) by vigorously eddying and further cen-
trifuged at 16,000×g for 20 min. Total 100 µL of the super-
natant was transferred to the HPLC autosampler vial, and 
then 1 µL was injected into the LC-MS/MS system for 
analysis.  
1.9  LC-MS/MS analysis of tolbutamide and 4-hydrox- 
ytolbutamide in plasma 
Analysis of tolbutamide and 4-hydroxytolbutamide in plas-
ma was performed on a HPLC coupled with tandem mass 
spectrometry (LC-MS/MS). The LC-MS/MS system con-
sists of an Agilent 1290 series HPLC and a 6460 triple 
quadrupole mass spectrometry (Agilent Technologies, 
USA). The 1290 HPLC was composed of a degasser, a bi-
nary pump, an autosampler and a thermostatic column 
compartment. The 6460 triple quadrupole mass spectrome-
try was equipped with an Agilent Jet Stream electrospray 
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ionization (ESI) source and operated with Agilent Mass-  
Hunter software (version 5.0.280.1, Agilent Technologies). 
The chromatographic separation was performed by an Ag-
ilent Zorbax Eclipse Plus C18 Rapid Resolution HT column 
(2.1 mm×50 mm, 1.8 µm) protected by a Phenomenex C18 
guard column (Torrance, USA). Mobile phase system of 
H2O containing 1 mmol L
1 ammonium acetate and 0.01% 
acetate acid (v/v) (A) and acetonitrile (B) was utilized. The 
two compounds together with IS were eluted by HPLC gra-
dient with a flow rate of 0.1 mL min1 as follows: 0–0.5 
min, 35% acetonitrile; 0.5–2.5 min, 35%–85% acetonitrile; 
2.5–4 min, 85% acetonitrile; 4–4.2 min, 85%–35% acetoni-
trile; 4.2–6 min, 35% acetonitrile. The temperature of col-
umn oven was maintained at 40°C and the total run time for 
sample analysis was 6.0 min. 
The mass spectrometer was operated in the negative ESI 
mode, and the detection of the ions was performed in the 
multiple reaction monitoring (MRM) mode, monitoring the 
transition of m/z 269.1 to the m/z 170.0 product ion for tol-
butamide, m/z 285.1 to m/z 186.0 product ion for 
4-hydroxytolbutamide, and m/z 275.0 precursor to m/z 
189.8 product ion for IS, respectively. MS/MS conditions 
were optimized as follows: drying gas temperature, 300°C; 
gas flow, 10 L min1; nebulizer, 25 psi; sheath gas tempera-
ture, 350°C; sheath gas flow, 11 L min1; collision gas (N2), 
1.6 MPa. The fragment energy was set at 110 V for all of 
the three compounds tested. The collision energy was opti-
mized to 12 eV for tolbutamide and 4-hydroxytolbutamide, 
and 14 eV for IS. A divert valve was used to divert the elu-
ent to waste from 0 to 2 min, 5.5 to 6 min, and to MS from 
2 to 5.5 min. 
1.10  Western blotting assay of rat CYP2C11 
A piece of rat liver tissue was homogenated in radio im-
munoprecipitation assay (RIPA) lysate buffer after 3 d CuE 
treatments. The homogenate was put into 80°C overnight 
for further dissociation. Frozen homogenate was thawed on 
ice, and then centrifuged at 13,000×g for 20 min at 4°C. 
The supernatant protein was collected and quantified using 
Micro BCA protein Assay Kit. For CYP2C11 immunoblot 
analysis, proteins (70 μg) from different treatment groups 
were resolved on 10% acrylamide gels and transferred to a 
nitrocellulose membrane. After blocking with bovine serum 
albumin (BSA, 5% w/v) in phosphate buffer with 0.1% 
tween-20 (PBST) for 1.5 h, the membrane was incubated 
with a primary antibody (1:1,000) from Abcam (UK) for rat 
CYP2C11 at 4°C overnight. After washing, the membrane 
was incubated with a fluorescence-conjugated secondary 
antibody to rabbit IgG (1:10,000) for 1.5 h. After washing, 
the blots on the membrane were visualized by the LI-COR 
Odyssey System and densitometry analysis performed with 
Odyssey 3.0 software (USA). 
1.11  Data analysis 
All data were expressed as the mean±standard error of mean 
( x ±SE). Statistical analysis of the data was carried out by 
one-way ANOVA, and the P values less than 0.05 were 
considered statistically significant. Enzyme kinetic parame-
ters were fitted by non-linear regression analysis for calcu-
lation of IC50 (concentration of inhibitor to cause 50% inhi-
bition of original enzyme activity) value using GraphPad 
Prism 5.0 (GraphPad Software Inc., USA). A Lineweaver- 
Burk Plot is a double reciprocal plot in which varying 
substrate concentrations are plotted against reaction veloci-
ties to obtain linear transformation. The enzyme parameter 
Michaelis constant Km and Vmax values were obtained from 
Lineweaver-Burk Plot. The inhibition constant (Ki) was 
obtained by a secondary plot using the slope of the primary 
Lineweaver-Burk Plot (Km/Vmax versus inhibitor concentra-
tion).  
Pharmacokinetic parameters such as half-time (T1/2), ini-
tial plasma concentration extrapolated to time zero (Cinitial), 
area under the plasma concentration-time curve during the 
period of observation (AUC0-T), area under the plasma con-
centration-time curve from zero to infinity (AUC0-∞), 
clearance (CL), apparent volume of distribution (Vd), and 
the mean residence time (MRT) were calculated by Win-
Nonlin software version 5.2.1 (Pharsight Corporation, USA) 
based on noncompartmental analysis. 
2  Results 
2.1  LC-MS/MS method validation for analysis of tol-
butamide and 4-hydroxytolbutamide in rat plasma 
Six different lots of blank rat plasma were checked for any 
false positive MS responses. As a result, no obvious inter-
ferences from endogenous plasma substances were observed 
and a good separation of the tolbutamide, 4-hydroxytol- 
butamide and chlorpropamide (IS) was achieved under the 
current LC-MS/MS conditions (Figure 2). The retention 
time of tolbutamide, 4-hydroxyltolbutamide and IS was 4.3, 
3.1, and 4.1 min, respectively (Figure 2). Calibration curves 
were confirmed by plotting the peak area ratio (y) of each 
analyte to IS versus plasma concentration (x) using weighed 
least squares regression analysis (1/x2), with good linearity 
(R2>0.98 for tolbutamide and R2>0.99 for 4-hydroxytol- 
butamide) over the concentration ranges (10–100 μg mL1 
for tolbutamide and 50–2000 ng ml1 for 4-hydroxytol- bu-
tamide, respectively). The accuracy and precision were 
evaluated by assaying quality control (QC) samples at low, 
medium and high concentrations on the same day and three 
consecutive days, according to the Food and Drug Admin-
istration (FDA) acceptance criteria. The accuracy was be-
tween 86.4%–101.7% for tolbutamide and 93.1%–111.3% 
for 4-hydrox-ytolbutamide, respectively. The intra- and  
inter-day precision was within 6.41% for tolbutamide and  
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Figure 2  Representative chromatograms after multiple reaction monitoring (MRM) of tolbutamide and 4-hydroxytolbutamide in rat plasma. A, A blank 
plasma sample. B, A blank plasma spiked with tolbutamide, 4-hydroxytolbutamide and IS at lower limit of quantification (LLOQ) sample. C, A plasma 
sample collected at 60 min after caudal intravenous administration of 10 mg kg1 tolbutamide in rats. 
7.68% for 4-hydroxytolbutamide, respectively. Therefore, 
the high selectivity and sensitivity of the LC-MS/MS assay 
was validated with short analytical time and easy sample 
treatment, and consequently would be suitable for pharma-
cokinetic studies. 
2.2  Effects of CuE on CYP2C11 (tolbutamide 
4-hydroxylase) activity in rat liver microsomes in vitro 
To evaluate the effect of CuE on CYP2C11 activity, tol-
butamide 4-hydroxylase activities with or without CuE were 
determined by using rat liver microsomes. CuE inhibited the 
formation of 4-hydroxytolbutamide (IC50=51.7 μmol L1) 
concentration-dependently with decreases in the 4-hydrox- 
ytolbutamide/tolbutamide ratios (Figure 3). Enzyme kinetics 
studies were carried out with various tolbutamide concen-
trations in the presence or absence of CuE and sulfaphena-
zole (positive control for rat CYP2C11 inhibition). The 
Lineweaver-Burk transformation of the enzyme velocities 
versus substrate concentration showed that CuE was a 
competitive inhibitor (Figure 4A). As shown in Figure 4B, 
the Ki value for CuE was 55.5 μmol L1 which was deter-
mined by a secondary plot using the slope of the primary 
Lineweaver-Burk plot. The inhibitory effect of CuE on tol-
butamide 4-hydroxylation was comparable to sulfaphena-
zole, a specific rat CYP2C11 inhibitor, with the Ki value at 
68.5 μmol L1. Moreover, time-dependent inhibition ex-
periments were also performed with 50 μmol L1 (ap-
proaching IC50) CuE to determine whether the inhibition of 
CYP2C11 activity by CuE was time-dependent. Results 
showed that no time-dependent inhibition was observed, 
indicating reversible inhibition. 
2.3  Effects of CuE treatment on 4-hydroxylation and 
pharmacokinetics of tolbutamide 
Figure 5A and B showed the plasma concentration-time 
profiles of tolbutamide and 4-hydroxytolbutamide, respec-
tively, after single dose treatment with CuE (50–200 µg 
kg1, i.p.). No significant difference (P<0.05) in tolbutamide 
pharmacokinetics was observed with the single administra-
tion although the T1/2 and AUC were increased and the 
clearance was decreased (Table 1). The enzyme inhibitor 
fluconazole (positive control) significantly delayed the 
elimination of tolbutamide starting from 120 min (Figure 
5A) by increasing the T1/2, AUC and MRT, and decreased 
the CL by 60.8% (Table 1). 
For the multiple-pretreatment study, the mean plasma 
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Figure 3 (color online)  Inhibition of CYP2C11 activity by CuE in rat liver microsomes, presented as 4-hydroxytolbutamide/tolbutamide ratios. Results 
were x ±SE of six rats. Statistical significance was determined by analysis of variance. **: P<0.01; ***: P<0.001. 
 
Figure 4 (color online)  Primary Lineweaver-Burk plot (A) and the secondary plot for Ki (B) in the inhibition of CYP2C11-mediated tolbutamide 
4-hydroxylase by various concentrations of CuE (5–50 mol L1) in rat liver microsomes. Tolbutamide was used at concentrations of 25, 50, 75 and 100 
mol L1. Each data point represents the mean of six rats. 
Table 1  Pharmacokinetics of tolbutamide (10 mg kg1, i.v.) in rats after a single administration of CuE (50–200 μg kg1, i.p.)a) 
Parameters Control 
Fluconazole 
60 mg kg1 
CuE treatment 
50 μg kg1 100 μg kg1 200 μg kg1 
T1/2 (min) 217.36±18.97 544.19±19.32
*** 245.23±11.21 242.43±25.34 263.32±12.65 
Cinitial (μg mL1) 80.19±6.99 75.47±2.18 74.29±5.15 69.64±4.20 76.95±4.08 
AUC 0-T (min μg mL1) 13,867.31±782.34 18,701.70±754.69** 14,680.75±370.82 14,622.76±616.34 14,111.75±385.60 
AUC 0-∞ (min μg mL1) 20,208.64±1,725.75 51,559.50±2,291.20*** 23,176.09±784.79 23,549.27±2,430.00 23,216.93±782.26 
Vd (mL kg
1) 153.90±5.19 152.86±6.61 152.44±3.59 148.51±3.29 163.74±6.20 
CL (mL min1 kg1) 0.51±0.04 0.20±0.01*** 0.43±0.01 0.44±0.04 0.43±0.01 
MRT (min) 139.23±2.84 164.17±0.95*** 145.31±1.84 144.77±2.62 146.11±1.07 
a) Fluconazole (60 mg kg1, i.p.) was used as a positive control for enzyme inhibition studies. Results were x ±SE of 5–8 animals. **: P<0.01; ***: 
P<0.001. 
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Figure 5 (color online)  Concentration-time profiles of (A) tolbutamide and (B) 4-hydroxytolbutamide after a single administration of CuE (50–200 g kg1, 
i.p.) after a standard dose of tolbutamide (10 mg kg1, i.v.). Results were x ±SE of 5–8 rats. *: P<0.05; **: P<0.01; ***: P<0.001. 
concentration-time profiles of tolbutamide and 4-hydroxy- 
tolbutamide after 3 d CuE pretreatment were shown in Fig-
ure 6A and B, respectively. As shown in Table 2, pretreat-
ment of CuE (200 µg kg1 d1, i.p.) for 3 d significantly de-
creased tolbutamide clearance by 25.0%, and significantly 
prolonged plasma half-life (T1/2) from (182.26±18.24)      
to (250.29±21.85) min. Other pharmacokinetic parameters 
(Cinital, AUC, MRT) of tolbutamide also increased compared 
with the control. In addition, pretreatment of CuE  
(200 µg kg1 d1, 3 d, i.p.) also decreased the formation of 
4-hydroxytolbutamide and the AUC0-T of 4-hydroxytol- 
butamide ((186,130±18,066) min ng mL1 vs. (147,991± 
12,382) min ng mL1) by 20.5% (P<0.05). These may re-
flect changes inhibited by CuE on the metabolism of tol-
butamide to 4-hydroxytolbutamide, and may be related to 
CYP2C11 inhibition. The effects of carbamazepine, an en-
zyme inducer, were as expected in terms of its ability to 
alter tolbutamide 4-hydroxylation and cause changes in the 
pharmacokinetic of tolbutamide (Table 2). 
2.4  Effects of CuE treatment on hepatic CYP2C11 ex-
pression 
To explore whether a 3 d CuE administration can affect 
CYP2C11 protein expression, the western blot assay was 
used to study the CYP2C11 protein expression in rat liver. As 
shown in Figure 7, CuE administration (50–200 µg kg1 d1,  
3 d, i.p.) only slightly inhibited CYP2C11 protein expres-
sion (P>0.05) in rat liver while carbamazepine (positive 
control for CYP2C11 induction) produced an expected in-
crease in CYP2C11 expression (P<0.05). This result was a 
part of the study complemented the in vitro and in vivo 
metabolic studies and clarified that CuE competitively in-
hibited the rat CYP2C11 activity without affecting the ex-
pression of CYP2C11 protein.  
3  Discussion 
The CYP2C subfamily in humans accounts for approxi-
mately 16% of the total hepatic P450 complement, and    
is responsible for the metabolism of 15% of drug oxida- 
tions [27]. CYP2C9 is a major CYP isoform to metabolize a 
wide range of therapeutic agents, including non-steroidal 
anti-inflammatory drugs, oral anticoagulants and oral hypo-
glycaemic agents, such as meloxicam, suprofen, tolbutam-
ide, and S-warfarin [22]. Moreover, CYP2C9 also contrib-
utes to the metabolism of fatty acids, prostanoids and ster-
oid hormones [21]. The rat forms of the human CYP2C9 
equivalent CYP2C isoforms include CYP2C6 and CYP2- 
C11, and CYP2C11 is a homologue of the human CYP2C9 
with 77% homology [21,22]. Moreover, the CYP2C11 as 
the most abundantly expressed CYP enzymes in male SD rats 
is very important, in a way equivalent to CYP3A4 in humans. 
Until now, tolbutamide 4-hydroxylase has been a widely used 
index reaction for the measurement of CYP2C9 (human) and 
CYP2C11 (rat) activity [21,22,28].  
Initial evidence that CuE may affect CYP-mediated me-
tabolism came from our previous studies in which CuE re-
duced the clearance of warfarin in vivo in rats [15]. One of 
the objectives of this study was to delineate the CuE- warfa-
rin interactions observed in rats, which may involve interac-
tion with CYP1A2 and/or CYP3A and/or CYP2C11. In this 
study, it is clear from the in vitro inhibition kinetic studies 
that CuE can competitively inhibit rat tolbutamide 
4-hydroxylase (CYP2C11) activity. Moreover, we also used 
the simultaneous nonlinear regression (SNLR) model [29] 
to make sure the competitive inhibition and get the Ki value   
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Figure 6 (color online)  Concentration-time profiles of (A) tolbutamide and (B) 4-hydroxytolbutamide after a 3 d administration of CuE (50–200 g kg1 
day1, i.p.) after a standard dose of tolbutamide (10 mg kg1, i.v.). Results were x ±SE of 5–8 rats. *: P<0.05; **: P<0.01; ***: P<0.001. 
Table 2  Pharmacokinetics of tolbutamide (10 mg kg1, i.v.) in rats after multiple pretreatments with CuE (50–200 μg kg1 d1, i.p.) for 3 da) 
Parameters Control 
Carbamazepine 
60 mg kg1 d1, 3 d 
CuE treatment 
50 μg kg1 d1, 
3 d 
100 μg kg1 d1, 
3 d 
200 μg kg1 d1, 
3 d 
T1/2 (min) 182.26 ±18.24 118.09 ±13.21
* 215.60 ±19.55 242.49 ±21.74 250.29 ±21.85* 
Cinitial (μg mL1) 68.71 ±4.55 62.55 ±3.23 68.27 ±5.84 71.99 ±3.89 72.71 ±3.29 
AUC 0T (min μg mL1) 12,227.19 ±669.35 9,644.59 ±658.73* 13,056.35 ±1,079.53 13,463.53 ±817.00 14,111.86 ±920.50 
AUC 0∞ (min μg mL1) 16,484.26 ±1,546.06 11,011.48 ±996.78* 19,669.24 ±2,433.98 21,120.10 ±2,196.18 22,190.16 ±2,172.22 
Vd (mL kg
1) 158.91 ±9.07 154.35 ±10.07 162.51 ±6.67 167.64 ±4.25 164.66 ±8.16 
CL (mL min kg1)  0.64 ±0.07 0.93 ±0.09** 0.56 ±0.07 0.51 ±0.06 0.48 ±0.04* 
MRT (min) 136.00 ±4.79 118.00 ±3.37* 140.17 ±3.10 140.71 ±2.06 145.93 ±2.76 
a) Carbamazepine (60 mg kg1 d1, i.p., 3 d) was used as a positive control for enzyme induction studies. Results were x ±SE of 5–8 animals. *: P<0.05; 
**: P<0.01. 
was 62.7 μmol L1, which was similar to 55.5 μmol L1 de-
termined by a secondary plot using the slope of the primary 
Lineweaver-Burk plot (Km,app method) [29]. Furthermore, 
the Ki value of CuE in rat liver microsomes was in the same 
range to that of sulfaphenazole, which was much more ef-
fective in inhibiting tolbutamide 4-hydrox- ylation in hu-
mans than in rats [20,28]. In addition, the present study also 
showed that the inhibition of CuE on CYP2C11 activity in 
vitro was only dose-dependent, and not time-dependent. 
Therefore, these results indicated that CuE is a reversible 
inhibitor of CYP2C11.  
The effects of CuE on CYP2C11 activity and expression 
have also been carried out in vivo to investigate any phar-
macokinetic changes of tolbutamide as well as potential 
enzyme inducing effects on CYP2C11 in rats. The dose of 
CuE was selected on the basis of our previous studies on the 
CuE-warfarin interactions [15]. The method of pretreatment 
of rats has also been used in our previous studies [30,31]. 
After a single pretreatment with CuE (50–200 µg kg1, i.p.), 
the pharmacokinetics of tolbutamide in rats did not signifi-
cantly change compared with the control. However, multi-
ple pretreatments of CuE (200 µg kg1 d1, 3 d, i.p.) resulted 
in a longer T1/2 and lower CL of tolbutamide compared with 
the control group. The distinction of the effects of CuE on 
the pharmacokinetics of tolbutamide by two pretreatments 
may be due to the different doses of CuE in rats. In fact, 
multiple doses may maintain a lasting and stable blood 
concentration to inhibit CYP2C11 activity in vivo, while a 
single dose may contribute to clearance of CuE, so the in-
hibitory effect is not obvious. 
On the other hand, CuE also showed strong hepatotoxi-
city after multiple doses administration (data not shown). 
Therefore, the hepatic injury which was attributed to the 
potent toxicity of CuE, may result in a longer T1/2 and lower 
CL of tolbutamide. At the same time, western blot analysis 
of rat CYP2C11 in this study confirmed that CuE has no 
inducing effects on rat CYP2C11 expression after 3 d CuE 
administration. Taken together results from previous study 
with CuE-warfarin and the current study, CuE may alter the 
metabolism and pharmacokinetic of model CYP2C11 sub-
strates. 
In summary, co-administration of CuE or herbal products  
 Liu J, et al.   Sci China Life Sci   February (2016) Vol.60 No.2 223 
 
Figure 7  Effects of CuE on CYP2C11 expression in the rat. Rats re-
ceived 3 d pretreatment according to the following groups. A, Control. B, 
Carbamazepine (60 mg kg1 d1, i.p.). C, CuE (50 µg kg1 d1, i.p.). D, CuE 
(100 µg kg1 d1, i.p.). E, CuE (200 µg kg1 d1, i.p.). Data were expressed 
as the x ±SE of six rats. *: P<0.05. 
rich in CuE may affect the metabolism of CYP2C11 sub-
strates though competitive inhibition and alter their clear-
ance. In addition, CuE had no effect on CYP2C11 protein 
expression after multiple treatments and confirmed that CuE 
did not produce CYP2C11 enzyme induction in the Spra-
gue-Dawley rat. This study offers a useful reference for the 
reasonable and safe use of herbal or natural products con-
taining CuE to avoid unnecessary drug-drug interactions. 
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